Sorafenib as a potential strategy for refractory pulmonary arterial hypertension

Gou Kimura, Masaharu Kataoka, Takumi Inami, Keiichi Fukuda, Hideaki Yoshino, Toru Satoh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases. We investigated the efficacy and safety of sorafenib for the treatment of patients with refractory pulmonary arterial hypertension (PAH). Sorafenib was started in 9 patients (7 with idiopathic PAH, 2 with pulmonary veno-occlusive disease) who had severe PAH and right heart failure, in spite of treatment with vasodilators specific for PAH. Sorafenib was started as an add-on therapy at a dose of 50 or 100 mg/day, and increased to 100–400 mg/day. New York Heart Association functional class improved in 8 patients and did not change in 1. Mean pulmonary arterial pressure improved in 6 patients (14–28% decrease) and did not apparently change in 2 (follow-up catheterization was not performed in 1 patient). The main adverse effects of sorafenib were skin reactions on the hands and feet, which appeared in 5 patients. They were tolerable in 4 patients, but discontinuation of sorafenib was needed in only 1 patient. In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events. Sorafenib is an alternative strategy for patients with refractory PAH.

Original languageEnglish
Pages (from-to)46-49
Number of pages4
JournalPulmonary Pharmacology and Therapeutics
Volume44
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Pulmonary Hypertension
Refractory materials
Pulmonary Veno-Occlusive Disease
sorafenib
Protein-Serine-Threonine Kinases
Vasodilator Agents
Tyrosine
Skin
Phosphotransferases
Catheterization
Protein-Tyrosine Kinases
Foot
Arterial Pressure
Therapeutics
Heart Failure
Hand
Safety
Lung

Keywords

  • Multi-kinase inhibitor
  • Pulmonary arterial hypertension
  • Pulmonary veno-occlusive disease
  • Right heart failure
  • Sorafenib

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Biochemistry, medical
  • Pharmacology (medical)

Cite this

Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. / Kimura, Gou; Kataoka, Masaharu; Inami, Takumi; Fukuda, Keiichi; Yoshino, Hideaki; Satoh, Toru.

In: Pulmonary Pharmacology and Therapeutics, Vol. 44, 01.06.2017, p. 46-49.

Research output: Contribution to journalArticle

Kimura, Gou ; Kataoka, Masaharu ; Inami, Takumi ; Fukuda, Keiichi ; Yoshino, Hideaki ; Satoh, Toru. / Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. In: Pulmonary Pharmacology and Therapeutics. 2017 ; Vol. 44. pp. 46-49.
@article{6d1879ac130844aba0b1577b777d20bf,
title = "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension",
abstract = "Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases. We investigated the efficacy and safety of sorafenib for the treatment of patients with refractory pulmonary arterial hypertension (PAH). Sorafenib was started in 9 patients (7 with idiopathic PAH, 2 with pulmonary veno-occlusive disease) who had severe PAH and right heart failure, in spite of treatment with vasodilators specific for PAH. Sorafenib was started as an add-on therapy at a dose of 50 or 100 mg/day, and increased to 100–400 mg/day. New York Heart Association functional class improved in 8 patients and did not change in 1. Mean pulmonary arterial pressure improved in 6 patients (14–28{\%} decrease) and did not apparently change in 2 (follow-up catheterization was not performed in 1 patient). The main adverse effects of sorafenib were skin reactions on the hands and feet, which appeared in 5 patients. They were tolerable in 4 patients, but discontinuation of sorafenib was needed in only 1 patient. In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events. Sorafenib is an alternative strategy for patients with refractory PAH.",
keywords = "Multi-kinase inhibitor, Pulmonary arterial hypertension, Pulmonary veno-occlusive disease, Right heart failure, Sorafenib",
author = "Gou Kimura and Masaharu Kataoka and Takumi Inami and Keiichi Fukuda and Hideaki Yoshino and Toru Satoh",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.pupt.2017.03.009",
language = "English",
volume = "44",
pages = "46--49",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Sorafenib as a potential strategy for refractory pulmonary arterial hypertension

AU - Kimura, Gou

AU - Kataoka, Masaharu

AU - Inami, Takumi

AU - Fukuda, Keiichi

AU - Yoshino, Hideaki

AU - Satoh, Toru

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases. We investigated the efficacy and safety of sorafenib for the treatment of patients with refractory pulmonary arterial hypertension (PAH). Sorafenib was started in 9 patients (7 with idiopathic PAH, 2 with pulmonary veno-occlusive disease) who had severe PAH and right heart failure, in spite of treatment with vasodilators specific for PAH. Sorafenib was started as an add-on therapy at a dose of 50 or 100 mg/day, and increased to 100–400 mg/day. New York Heart Association functional class improved in 8 patients and did not change in 1. Mean pulmonary arterial pressure improved in 6 patients (14–28% decrease) and did not apparently change in 2 (follow-up catheterization was not performed in 1 patient). The main adverse effects of sorafenib were skin reactions on the hands and feet, which appeared in 5 patients. They were tolerable in 4 patients, but discontinuation of sorafenib was needed in only 1 patient. In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events. Sorafenib is an alternative strategy for patients with refractory PAH.

AB - Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases. We investigated the efficacy and safety of sorafenib for the treatment of patients with refractory pulmonary arterial hypertension (PAH). Sorafenib was started in 9 patients (7 with idiopathic PAH, 2 with pulmonary veno-occlusive disease) who had severe PAH and right heart failure, in spite of treatment with vasodilators specific for PAH. Sorafenib was started as an add-on therapy at a dose of 50 or 100 mg/day, and increased to 100–400 mg/day. New York Heart Association functional class improved in 8 patients and did not change in 1. Mean pulmonary arterial pressure improved in 6 patients (14–28% decrease) and did not apparently change in 2 (follow-up catheterization was not performed in 1 patient). The main adverse effects of sorafenib were skin reactions on the hands and feet, which appeared in 5 patients. They were tolerable in 4 patients, but discontinuation of sorafenib was needed in only 1 patient. In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events. Sorafenib is an alternative strategy for patients with refractory PAH.

KW - Multi-kinase inhibitor

KW - Pulmonary arterial hypertension

KW - Pulmonary veno-occlusive disease

KW - Right heart failure

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85015929912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015929912&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2017.03.009

DO - 10.1016/j.pupt.2017.03.009

M3 - Article

VL - 44

SP - 46

EP - 49

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

ER -